The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest ...

(NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the United ...

1Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2Cancer Biology PhD Program, University of South Florida, Tampa, Florida.

The study involved in vitro assays and in vivo mouse models to evaluate the efficacy of these modified CAR-T cells. Results demonstrated that the armed CAR-T cells exhibited significantly stronger ...

Adding serial circulating tumor DNA (ctDNA) assays to standard of care imaging surveillance had limited clinical benefits in patients with resected colorectal cancer (CRC). Among a cohort of ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...

In addition, GBM cell tumors are very resistant to radiation and cytotoxic chemotherapy (2 ... Moreover, DPG decreased the viability and sphere formation of the cultured stem cell-enriched populations ...

HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Hematological Tumor. According to GlobalData ... HMPL’s research and development programs comprise ...

Sphere Fluidics, announced the launch of Cyto-Cellect® Fc Fusion, a novel assay designed to accelerate cell line development for Fc fusion manufacturing. Cyto-Cellect® Fc Fusion is a robust, ...